<DOC>
	<DOCNO>NCT00030823</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response decrease recurrence breast cancer . PURPOSE : Pilot trial study effectiveness vaccine therapy treat patient high risk breast cancer recurrence .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients High Risk Breast Cancer Recurrence</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether immunization multiple antigens comprise GM2 , Globo-H , Lewis , TF ( c ) , sTn ( c ) , Tn ( c ) , glycosylated MUC-1 32 ( aa ) conjugate keyhole limpet hemocyanin plus QS21 induce antibody response individual antigen breast cancer cell express antigen patient high risk breast cancer recurrence . - Determine toxic effect regimen patient . OUTLINE : Patients receive Globo-H-GM2-Lewis-y-MUC1-32 ( aa ) -sTn ( c ) -TF ( c ) -Tn ( c ) -KLH conjugate vaccine QS21 adjuvant subcutaneously weekly week 1 , 2 , 3 , 7 , 19 . Patients follow every 3 month . PROJECTED ACCRUAL : A total 30 patient accrue study within 2-3 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<mesh_term>Keyhole-limpet hemocyanin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis breast cancer high risk recurrence , define one following : Stage IV free know disease eradication surgery , radiotherapy , chemotherapy May may elevate CA 153 CEA level Stage I , II , III previously treat adjuvant chemotherapy clinically free identifiable disease , rise CA 153 CEA level Rising CA 153 CEA define prior normal level increase 2 consecutive occasion least 2 week apart For patient significant history smoke chronically elevate CEA ( less 15 ) , CEA must increase least 1.5 time uppermost chronic value 2 consecutive occasion least 2 week apart Stage III complete adjuvant therapy 24 month ago Recurrence ipsilateral axilla lumpectomy and/or axillary dissection modify radical mastectomy Recurrence ipsilateral breast lumpectomy and/or axillary dissection Stage II least 4 positive axillary node complete adjuvant therapy 24 month ago Stage IV stable hormonal therapy Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Male female Menopausal status : Not specify Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : Lymphocyte count least 500/mm^3 WBC least 3,000/mm^3 Hepatic : AST great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 1.5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No clinically significant New York Heart Association class III IV cardiac disease Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception No prior seafood allergy No known prior immunodeficiency autoimmune disease No active cancer except basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 week since prior immunotherapy No prior vaccine antigen study Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics At least 4 week since prior surgery Concurrent surgery local recurrence allow patient remains disease free</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>